One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.

Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ

Diabetes care5 Feb 2009Cited by 302 (Europe PMC)

PMID19196887PMCIDPMC2671094DOI10.2337/dc08-1797PepBankPUB-19196887

Read at source PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In metformin-treated patients with type 2 diabetes, exenatide increased stimulated C-peptide secretion more than insulin glargine.
In plain wordsIn patients with diabetes, exenatide increased stimulated C-peptide secretion more than insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseStimulated C-peptide secretion
Study
n = 69
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
Relative secretion change
2.46 fold
exenatide versus insulin glargine
Source sentences
Summary
Treatment-induced change in combined glucose- and arginine-stimulated C-peptide secretion was 2.46-fold (95% CI 2.09-2.90, P < 0.0001) greater after a 52-week exenatide treatment compared with insulin glargine treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomly assigned to exenatide (n = 36) or insulin glargine (n = 33). beta-Cell function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week 52, and after a 4-week off-drug period.
Report a problemFND-1919688701
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, A1C reductions were similar with exenatide and insulin glargine.
In plain wordsIn patients with diabetes, exenatide and insulin glargine reduced A1C similarly.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeA1C reduction
Study
n = 69
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
A1C change
−0.8%
exenatide
A1C change
−0.7%
insulin glargine
Source sentences
Summary
Both exenatide and insulin glargine reduced A1C similarly: -0.8 +/- 0.1 and -0.7 +/- 0.2%, respectively (P = 0.55).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomly assigned to exenatide (n = 36) or insulin glargine (n = 33). beta-Cell function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week 52, and after a 4-week off-drug period.
Report a problemFND-1919688702
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced body weight compared with insulin glargine.
In plain wordsIn patients with diabetes, exenatide reduced weight compared with insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 69
Comparator
Insulin glargine
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
Weight difference
−4.6 kg
exenatide versus insulin glargine
Source sentences
Summary
Exenatide reduced body weight compared with insulin glargine (difference -4.6 kg, P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomly assigned to exenatide (n = 36) or insulin glargine (n = 33). beta-Cell function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week 52, and after a 4-week off-drug period.
Report a problemFND-1919688703

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

04HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, beta-cell function returned to pretreatment values after withdrawal of either exenatide or insulin glargine.
In plain wordsIn patients with diabetes, beta-cell function returned to pretreatment levels after either treatment stopped.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedBeta-cell function after withdrawal
Study
n = 69
Comparator
Pretreatment
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
beta-Cell function measures returned to pretreatment values in both groups after a 4-week off-drug period.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomly assigned to exenatide (n = 36) or insulin glargine (n = 33). beta-Cell function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week 52, and after a 4-week off-drug period.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1919688704
05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, A1C returned to pretreatment values after discontinuation of either exenatide or insulin glargine.
In plain wordsIn patients with diabetes, A1C returned to pretreatment values after either treatment stopped.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseA1C after withdrawal
Study
n = 69
Comparator
End of treatment
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
A1C and body weight rose to pretreatment values 12 weeks after discontinuation of either exenatide or insulin glargine therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomly assigned to exenatide (n = 36) or insulin glargine (n = 33). beta-Cell function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week 52, and after a 4-week off-drug period.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1919688705
06HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, body weight returned to pretreatment values after discontinuation of either exenatide or insulin glargine.
In plain wordsIn patients with diabetes, weight returned to pretreatment values after either treatment stopped.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBody weight after withdrawal
Study
n = 69
Comparator
End of treatment
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
A1C and body weight rose to pretreatment values 12 weeks after discontinuation of either exenatide or insulin glargine therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomly assigned to exenatide (n = 36) or insulin glargine (n = 33). beta-Cell function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week 52, and after a 4-week off-drug period.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1919688706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00097500

Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

AstraZenecan = 69Sept 2004 to Dec 2009

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 7 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.